25 Mar 2023

Curated GI articles March 24th, 2023: Microbiome co raises €13M | Medtronic, NVIDIA AI platform for GI | SV Bank failure & docs

Curated GI articles March 24th, 2023:
Microbiome co raises €13M | Medtronic, NVIDIA AI platform for GI | SV Bank failure & docs
Medtronic and NVIDIA Collaborate to Build AI Platform for Medical Devices (NVIDIA)
Integrating NVIDIA technology into Medtronic’s real-time AI endoscopy device to help improve patient care and outcomes. Here’s Praveen’s post on the first ever GI Genius Summit.
‘Physician payment is always in the crosshairs’: How reimbursement rates affect gastroenterologists (Becker’s GI & Endoscopy)
The combination of decreased physician reimbursements and increased procedure costs continues to put physician pay in peril.
Vivante Expands Virtual GI Care with AI-Driven Care Plans (HIT Consultant)
Users will now receive AI-driven, personalized care plans guided by an expert team of coordinated care providers including gastroenterologists, internal medicine specialists, dietitians and health coaches.
Working in healthcare hasn’t gotten better. Career changes are still rising (Linkedin)
Healthcare professionals are continuing to make job transitions at a rapid pace compared to pre-pandemic, with the number of career changes last year topping even 2021’s dramatic spike.
AI-assisted colonoscopy doesn’t always improve adenoma detection: Study (MDedge)
Computer-aided detection (CADe) during colonoscopy may not lead to major improvements in key measures, particularly in community-based settings, according to a new study.
AGA launches ‘My IBD Life’ campaign to provide resources, support for patients, physicians  (Healio)
With recent data highlighting the emotional and social challenges of inflammatory bowel disease, AGA has launched the My IBD Life campaign to address the growing need for psychosocial support in patient care.
In Low-Risk Patients, Colonoscopy Interval May Go Beyond 10 Years (GI & Endoscopy News)
A negative result on a screening colonoscopy appears to be highly predictive of no colorectal cancer even when screening intervals exceed 10 years, according to a recent large study.
Silicon Valley Bank failure: What physicians need to know (Medical Economics)
Many physicians are concerned and seeking advice if they should move their money from local banks to larger banks.
Microbiome therapeutics biotech mbiomics raises €13M (Labiotech)
mbiomics said it can spearhead the emerging field of synthetic microbial consortia with the potential to revolutionize the treatment of a wide range of diseases, from cancer to inflammatory bowel diseases.
Digital Lifestyle Intervention Tools May Help Patients With NAFLD (Medscape)
Digital therapeutics (DTx), which provide evidence-based interventions through software programs, could benefit patients with nonalcoholic fatty liver disease (NAFLD), according to a new review.
Diagnosing and Treating Functional GI Disorders with a Multidisciplinary Team Approach (CDI)
Functional gastrointestinal (GI) disorders can significantly impact a patient’s quality of life, and effective diagnosis and treatment require a multidisciplinary approach.
No Clear Patterns Emerging in Crohn’s Disease Treatment Outcomes in Recent Years (HCP Live)
An overview of treatment outcomes for patients with Crohn’s disease showed no discernable patterns in clinical remission and response has emerged in recent years.
Guardant Health collaborates with The Ohio State University Comprehensive Cancer Center to study colorectal cancer screening adherence (Business Wire)
The Ohio State University-led study will evaluate changes in CRC screening adherence in underserved urban and rural communities.
Research: What Happens When Private Equity Firms Buy Hospitals? (Harvard Business Review)
An analysis published in the Harvard Business Review suggests that policy discussions around private equity in healthcare should move beyond simplistic labeling of the practice as either “good” or “bad”.
Advantages Shown for Endoscopic Management of Necrotizing Pancreatitis (GI & Endoscopy News)
Endoscopic management of necrotizing pancreatitis alone or with percutaneous drainage of symptomatic pancreatic fluid collections has multiple advantages over surgery or percutaneous drainage alone.
Previse Closes $3M Seed To Tackle Early Cancer Detection And Launches Company’s First Esophageal Cancer Prognostic Test (PR Newswire)
Capsulomics, announces official rebrand as Previse and launches their first product to enable accurate prognosis and detection data for those prone to Esophageal Cancer.
Physician Suicide: Investigating Its Prevalence and Cause (Medscape)
Physicians are admired for their sacrifice and dedication. Yet beneath the surface lies a painful, quiet reality: Physicians may take their lives more than any other professional.
Partnership to Support National Gastroenterology-Focused Clinical Registry (Health IT Analytics)
The GI Quality Improvement Consortium, Inc. has tapped Health Catalyst to address data entry and management challenges within its clinical registry.


Why Is Colorectal Cancer Rising in Younger People? (Medscape)

Lone star tick bites may be to blame for unexplained digestive problems (Medical Xpress)

A Physician’s Visual Guide To Artificial Intelligence (The Medical Futurist)

Colorectal cancer screening rates rose significantly after USPSTF lowered recommended age (Healio)

‘We’re getting much more aggressive’: Microsoft’s Nuance adds GPT-4 AI to its medical note-taking tool (STAT)

6 Tips for Gastroenterology Providers Treating Patients With Autism (GI & Endoscopy News)

Tell UnitedHealthcare to stop new prior authorization requirements (AGA)

In Barrett Esophagus Surveillance, Slower Is Better (Medscape)

Could the gut microbiota explain why inflammatory bowel diseases are on the rise? (Gut Microbiota for Health)

Videos: Interviews with GI Leaders  (Scope Forward Show/NextServices)

COVID-19: The Way Forward for Gastroenterology Practices
COVID-19 is a double whammy of both clinical and business disruption. This ebook will help you explore possible scenarios and be a guide in your plans for the future.
18 Mar 2023

Curated GI articles March 17th, 2023: AGA Shark Tank winner | Gut on a chip | 4 GI device innovations

Curated GI articles March 17th, 2023:
AGA Shark Tank winner | Gut on a chip | 4 GI device innovations
This reimbursement issue poses a ‘real challenge’ for gastroenterologists (Becker’s GI & Endoscopy)
Vivek Kaul, MD, Segal-Watson professor of medicine in the gastroenterology and hepatology division at the University of Rochester (N.Y.) Medical Center, discusses the biggest challenge GIs face regarding reimbursement rates for GI procedures.
And the winner of this year’s Shark Tank is… (AGA)
Find out which of the five finalists was declared the winner at last week’s AGA Tech Summit.
ctDNA Testing in Colorectal Cancer Deemed Promising but Not Ready for Prime Time (Cancer Therapy Advisor)
Researchers maintain that additional studies are needed to confirm whether and how ctDNA testing should be used in practice.
‘Highly effective care’ boosted by collaboration between GI dietitians, psychologists (Healio)
In gastroenterology, two key members of a care team — GI dietitians and GI psychologists — work together to improve their patients’ nutritional status, manage gastrointestinal symptoms and enhance food-related and overall quality of life.
Four gastroenterology device innovations doctors need now (Medical Design & Outsourcing)
Two gastroenterologists share what device innovations would help in better diagnosing and treating gastrointestinal diseases.
Personalised nutrition startup Zoe stomachs $2.5 million (Tech.eu)
Adding on to a $38 million Series B extension round, London’s not-yet-available-in-the-UK personalised nutrition startup Zoe welcomes a new member to the cap table.
AGA clinical practice update: Telemedicine in gastroenterology (MDedge)
Dr. Gellad and colleagues penned a clinical practice update based on recently published studies and the experiences of the authors, who are active gastroenterologists and hepatologists.
Private Equity And The Monopolization Of Medical Care (Forbes)
As more doctors from a particular specialty and/or community join up, private equity firms raise prices on their behalf, knowing insurers will have no choice but to agree.
Disconnect Between ACG/AGA Guidelines and Insurance Policies on IBD Biologics (GI & Endoscopy News)
Many major insurance companies do not adhere to the most recent recommendations on inflammatory bowel disease treatment from the AGA and the ACG, according to an analysis of insurance company policies.
Doctors Aren’t Burned Out From Overwork. We’re Demoralized by Our Health System (NY Times)
A report estimated that in 2021 alone, about 117,000 physicians left the work force, while fewer than 40,000 joined it. This has worsened a chronic physician shortage.
Physicians say prior authorization rules harm patients, AMA survey finds, as CMS works toward new policy (Healthcare Dive)
Over a third of physicians said the requirements led to a serious adverse event for one of their patients, such as hospitalization, permanent impairment or death, the survey found.
Mayo Clinic Healthcare expert: Artificial intelligence improves colonoscopy accuracy (Mayo Clinic)
Artificial intelligence can be added to a traditional colonoscopy to identify polyps that otherwise might be overlooked.
Top 5 best paying cities for gastroenterologists (Becker’s GI & Endoscopy)
A list of the top five best paying cities for gastroenterologists of any experience level in any practice setting and their respective average salaries.
Novel artificial intelligence–enabled deep learning system to enhance adenoma detection: a prospective randomized controlled study (Science Direct)
This study assesses clinical quality outcomes during white-light colonoscopy with and without a novel AI computer-aided detection system.
ACG Issues Updated Guidance on Gastroparesis (GI & Endoscopy News)
Lead author Michael Camilleri, MD, DSc, a gastroenterologist and professor of medicine, physiology and pharmacology at Mayo Clinic in Rochester, Minn., about the impetus for the guideline and what it means to GI practice.
Gut on a Chip: Another Step Forward in Microbiome Research (Medscape)
An emerging technology, called “gut on a chip,” promises to open the door to experiments never before possible and promising to advance medical research, according to a new paper.
Four Reasons Why Clinical Research Can Be a Natural Fit for Private Practices (Nashville Medical News)
Participating in a clinical trial can have clear benefits for both a private practice and the patients they serve.
COVID Raises Risk for Long-Term GI Complications (Medscape)
People who have had COVID-19 have a 36% overall higher risk of developing gastrointestinal problems in the year after infection than people who have not had the illness, a large new study indicates.


Biden 2024 Budget Proposal Includes Billions for Cancer Moonshot (Medscape)

Colonoscope market to hit $6B by 2030 (Becker’s GI & Endoscopy)

Are You Misdiagnosing IBS? Watch Out for This Mimic (Medscape)

Increasing CRC Screening Rates in Latino Communities (awareness and access to care are key to success) (Gastro Broadcast)

MetaPhy Launches MyCare Program at Digestive Health Center in Thibodaux, LA (MetaPhy Health)

NYC Health + Hospitals/Harlem CEO Shares Colonoscopy Experience on Video to De-Stigmatize Life-Saving Procedure (NYC Health and Hospitals)

Oshi Health appoints new CFO, CCO (Becker’s GI & Endoscopy)

Endoscopic Sleeve Gastroplasty May Have Advantages Over Balloon (GI & Endoscopy News)

Videos: Interviews with GI Leaders  (Scope Forward Show/NextServices)

COVID-19: The Way Forward for Gastroenterology Practices
COVID-19 is a double whammy of both clinical and business disruption. This ebook will help you explore possible scenarios and be a guide in your plans for the future.
11 Mar 2023

Curated GI articles March 10th, 2023: The future of GI care | Would a smart toilet leak private info?

Curated GI articles March 10th, 2023:
The future of GI care | Would a smart toilet leak private info?
Payers may unintentionally be driving independent gastroenterologists to hospitals (Becker’s GI & Endoscopy)
Robert Pecha, MD, president of Gastroenterology Medical Clinic in Folsom, Calif., discusses his difficulties communicating with payers as a small, independent gastroenterology practice.
UK Cancer Detection Firm CanSense Raises £1.5M for Development of Colorectal Cancer Test (360Dx)
CanSense’s test is a blood-based assay that uses laser spectroscopy and artificial intelligence to identify early-stage colorectal cancer and precancerous polyps.
Podcast: Electrical mapping of the stomach! (GI StartUp Podcast)
Greg O’Grady, MD, founder and CEO of Alimetry on non-invasive mapping of gastric electrical activity to aid in Dx and Rx of gastric disorders.
The Future of GI Care (Titans of Healthcare)
What does the future of GI care look like? How will advancements in healthcare policies and technology, including AI, impact the GI community? Four GI leaders share their insights.
Healthcare’s Great Untethering: Why doctors, nurses and therapists are ditching full-time employment (LinkedIn)
What would happen if more and more clinicians chose not to have a full-time job and instead pursued contract work and self-employment? This LinkedIn Special Report tracks the rise in the number of doctors, nurses, and mental health therapists who are doing just that.
Digestive and Liver Health Specialists Opens State-of-the-Art Gastroenterology Care In 3 New Locations in Tennessee (EIN Newswires)
Led by double board-certified physicians Dr. Stephanie Pointer and Dr. Saras Sharma, the practice offers patients expert and compassionate care for all GI and liver diseases.
Are Physicians With MBAs Traitors to Healthcare? (MedPage Today)
Arthur Lazarus, MD, MBA shares his opinions on the great MD/MBA debate.
Salvo launches first-ever Remote Patient Monitoring enablement for GI chronic conditions (Salvo Health)
Salvo Health announces the first-to-market RPM offering for GI chronic conditions, including IBS, GERD/reflux, dyspepsia, Celiac, SIBO, and more to optimize clinical outcomes and boost practices for participating partners.
‘Follow the money’: 13 leaders on management trends in 2023 (Becker’s ASC)
Kevin Seely. CEO, Centers for Gastroenterology (Fort Collins, Colo.), and 12 healthcare leaders discuss how leadership structure at ASCs, hospitals and health systems could be affected by the evolving healthcare landscape.
Clario, GI Reviewers and RSIP Vision Team Up to Present a New AI Solution to Advance Clinical Trials for Inflammatory Bowel Diseases (PR Newswire)
Innovative, human-level AI technology will improve efficiency and consistency of Inflammatory Bowel Disease (IBD) scoring, advancing clinical trials of novel treatments for these debilitating ailments.
Biomerica announces the Launch of InFoods IBS as a Laboratory Developed Test (LDT); First patient samples have been processed (Globe Newswire)
Clinical trial data shows InFoods® IBS treatment diet significantly improved several key IBS symptoms including Abdominal Pain Intensity (API).
Pros and Cons of Breath Testing for Small Intestinal Bacterial Overgrowth and Intestinal Methanogen Overgrowth (Gastroenterology & Hepatology)
Like any clinical test, breath testing has inherent strengths and limitations, and results must be interpreted with consideration of the clinical context and influencing factors.
AI-Assisted Colonoscopy in IBD: Not All It’s Cut Out to Be? (Medscape)
Within the rising tide of studies extolling the benefits of artificial intelligence (AI) for improving adenoma detection during colonoscopy comes new research suggesting the contrary, at least among people with IBD.
The Amazon-One Medical, CVS-Oak Street Mashup: A Cautionary Note On Retail’s Incursion Into Healthcare Delivery (Forbes)
The deals could transform the industry and the patient experience, but they could also be disastrous and highly-public failures.
Small Talk, Big Topics tackles how to develop clinical expertise (AGA)
Small Talk, Big Topics hosts Drs. Matthew Whitson and CS Tse examine how to become a clinical expert with guests Drs. Rena Yadlapati and Frank Scott.
Oshi Health Takes Top Honors at ATA Telehealth Innovators Challenge For Its Proven, Reimbursed Digestive Care Model (PR Web)
Oshi doubles down with people’s choice wins for Best in Show and the Inpatient Care Solutions category.
Would a smart toilet leak your private info? (Futurity)
Smart toilets could detect disease early, but squeamishness and privacy concerns could impede their use.
Emotional, behavioral barriers decrease FIT-based CRC screening by up to 47% (Healio)
Defensive strategies, such as denying immediacy of testing or exempting oneself, are key barriers to at-home colorectal cancer screening, according to study results published in Cancer.


Reported HIPAA complaints and breaches shot up from 2017 to 2021: HHS (The Hill)

Exclusive: Ryse Health draws $6.5M Series A for hybrid diabetes care (Axios)

AMSURG Performs More Than 1 Million Colonoscopies in 2022, Helping Prevent Colorectal Cancer and Save Lives (Business Wire)

Oshi Health appoints new CFO, CCO (Becker’s GI & Endoscopy)

Racial and ethnic disparities persist in colorectal cancer screening (Healio)

Artificial intelligence for the histological prediction of ulcerative colitis remission (News Medical)

Welcome new AGA board members! (AGA)

Biden seeks to extend solvency of Medicare to 2050s (Healio)

How telehealth can save providers’ sanity and keep them in the profession (Health Data Management)

We took ChatGPT in for a Clinical NLP checkup (Medium)

Key Takeaways From the 2023 Healthcare Private Equity and Finance Conference (Lexology)

Videos: Interviews with GI Leaders  (Scope Forward Show/NextServices)

COVID-19: The Way Forward for Gastroenterology Practices
COVID-19 is a double whammy of both clinical and business disruption. This ebook will help you explore possible scenarios and be a guide in your plans for the future.
18 Feb 2023

Curated GI articles March 3rd, 2023: Medscape GI happiness & burnout report 2023 | What role should PE play in GI?

Curated GI articles March 3rd, 2023:
Medscape GI happiness & burnout report 2023 | What role should PE play in GI?
What role should private equity play in gastroenterology? (Becker’s GI & Endoscopy)
Robbie Allen, CEO of One GI, recently connected with Becker’s to discuss what role private equity should play in gastroenterology.
Medscape Gastroenterologist Lifestyle, Happiness & Burnout Report 2023: Contentment Amid Stress (Medscape)
Even as COVID-19’s effects on the workplace wane, many gastroenterologists are struggling to find the same level of contentment that they enjoyed before the pandemic hit.
Dr. Srinadh Komanduri and How Can AI and Other GI Innovations Add Value (The Scope with Dr. K)
Dr. K is accompanied by Dr. Srinadh Komanduri, chair of the AGA’s Center for GI Technology, they discuss new GI technologies and the digital empowerment revolution.
CMS lowers CRC screening coverage age, requires new modifier for follow-up colonoscopy (Healio)
CMS has announced expanded coverage for specific colorectal cancer screening tests by lowering the minimum age to include individuals aged 45 years and older under Medicare Part B.
Digital Therapeutics Could Help Patients With IBS (Medscape)
Several digital therapeutics (DTx) — evidence-based interventions delivered via mobile app or web-based platforms — could help patients with irritable bowel syndrome.
Podcast: Sam Jactel, Founder & CEO of Ayble Health (Becker’s GI & Endoscopy)
Sam Jactel (Founder & CEO of Ayble Health) discusses his background & what motivated him to start Ayble Health, trends he is watching in the GI space, and more.
12 Great Money Apps to Help Docs Grow Their Wealth (Medscape)
Such apps can be particularly helpful for physicians, whose notoriously packed schedules may not leave them much time to manage their finances.
AI in Clinical Medicine: A Practical Guide for Healthcare Professionals (WILEY)
From radiology, to pathology, dermatology, endoscopy, robotics, virtual reality, and more, AI in Clinical Medicine: A Practical Guide for Healthcare Professionals explores all recent state-of-the-art developments in the field.
3 gastroenterologists’ secrets to successful ASC ownership (Becker’s GI & Endoscopy)
Three gastroenterologists connected with Becker’s to share their secrets to successful ASC management amid ongoing changes in the industry.
The Arrival of Intestinal Ultrasound for Inflammatory Bowel Disease Care in the United States
(Gastroenterology & Hepatology)
This article provides information about the use of IUS in IBD, and summarizes strategies to overcome existing barriers to IUS implementation, including the newly available US-based training pathway and appropriate billing practice.
Iterative Health Accelerates Clinical Trial Recruitment Through Partnership with Florida Research Institute (Business Wire)
The two organizations will help to democratize access to novel IBD therapeutics for all patients, regardless of where they receive care.
Physician practice exit considerations (Physicians Practice)
What you should consider before stepping away from your practice. The article is aimed at any physician contemplating exiting their practice at some point.
Lifespan of GI: March 2023 Issuse of The American Journal of Gastroenterology (AJG)
This issue addresses GI conditions and preventive care across all stages of life, ACG Clinical Guideline for the diagnosis and management of Biliary Strictures and more.
GIQuIC Registry Announces New Partnership with Health Catalyst (Newswise)
Working in tandem, GIQuIC and Health Catalyst plan to transition existing registry operations for colonoscopy and esophagogastroduodenoscopy (EGD) procedures by the beginning of 2024.
VIDEO: Women in GI should dispel ‘myth of the Superwoman,’ be best versions of themselves (Healio)
In a Healio video exclusive, Aline Charabaty, MD, encourages women in gastroenterology to reject the notion of being “Superwoman” and instead focus on creating an optimal work-life balance.
New requirements for gastroenterology services- changes in prior authorization requirements  (UnitedHealthcare)
United commercial plan member patients will need to obtain prior authorization for gastroenterology endoscopy services.
Biosimilars Gastroenterology Roundup: February 2023 (The Center For Biosimilars)
As a new wave of biosimilars to treat inflammatory bowel disease enter the US market, a lot of clinical and policy news regarding adalimumab and infliximab biosimilars emerged throughout the month of February.
Mortality increases substantially with fibrosis stage in NAFLD (MDedge)
The risks of all-cause and liver-related mortality increase substantially based on fibrosis stage in biopsy-confirmed nonalcoholic fatty liver disease (NAFLD).


Network with GI tech thought leaders (AGA)

Digestive and Liver Health Specialists Opens State-of-the-Art Gastroenterology Care In 3 New Locations in Tennessee (EIN News)

World’s Best Specialized Hospitals 2023: Gastroenterology (Newsweek)

CMS must level playing field for independent physicians (Medical Economics)

Evolutions in endoscopy (MDedge)

Dr. David Heydt Named Medical Director of Capital Digestive Care Laboratory (Benzinga)

Medtronic’s GI sales grow in Q3 of fiscal year 2023 (Becker’s GI & Endoscopy)

Intermountain Health offers a tour through the human colon for cancer awareness (ABC4)

Covenant Physician Partners Now Incorporates Artificial Intelligence System for Enhanced Colonoscopy Screenings in Hawaii (Business Wire)

Wyckoff Heights Medical Center gets $2 mil grant to expand gastrointestinal wing (Brooklyn Paper)

AMA physician burnout webinar (AMA)

Consolidated Appropriations Act of 2023: New law brings retirement plan changes (Healio)

Videos: Interviews with GI Leaders  (Scope Forward Show/NextServices)

COVID-19: The Way Forward for Gastroenterology Practices
COVID-19 is a double whammy of both clinical and business disruption. This ebook will help you explore possible scenarios and be a guide in your plans for the future.
13 Feb 2023

Curated GI articles February 10th, 2023: Why 2022 was a ‘really good year’ for PE deals | 29% docs work side gigs

Curated GI articles February 10th, 2023:
Why 2022 was a ‘really good year’ for PE deals | 29% docs work side gigs
Vibrating Pill for Constipation Now Available (Medscape)
Vibrant was approved by the FDA in August but is just now becoming available for doctors to prescribe.
8 Things to Know About the Gastroenterologist Shortage (Healthgrades)
An aging U.S. population and growing demand may cause a substantial shortage in gastroenterologists as soon as 2025.
Midcareer vs. late-career gastroenterologist salary in the 5 largest cities (Becker’s GI & Endoscopy)
Here is the average salary for midcareer and late-career gastroenterologists in any practice setting in the five most populated cities in the U.S.
Why 2022 was ‘a really good year’ for private equity healthcare deals (Advisory Board)
According to a PitchBook analysis published Monday, private equity firms announced or closed an estimated 863 deals with healthcare organizations in 2022.
Setting higher standards for digital health technologies (MDedge)
Gastroenterologist Simon C. Mathews, MD, sees himself as a disciple of patient safety and quality improvement. In particular, he’d like to see noninvasive diagnostic technologies in the gastroenterology world become more patient-centric.
Artificial Intelligence is Forging a New Future for Gastroenterology (Mayo Clinic)
Researchers at Mayo Clinic are investigating how artificial intelligence can be harnessed to increase polyp detection.
Surveillance in Barrett’s Esophagus: Challenges, Progress and Possibilities (Science Direct)
The publication summarizes what is coming down the pike for enhancements in the detection of dysplasia and cancer in patients with Barrett’s Esophagus.
If You’re Caring for Patients, Don’t Forget to Take Care of Yourself (how to reduce stress and address burnout) (Gastro Broadcast)
Dr. Rosenberg and Ms. Kanarowski explore ways that physicians can recognize signals from their parasympathetic nervous system and develop self care tools to address stress and burnout.
IBD and Eating: New Website Offers ‘Gut Friendly’ Recipes (Medscape)
The Crohn’s & Colitis Foundation, in conjunction with Nestlé Health Sciences, launched the Gut Friendly Recipes site to help people create meals without missing out on nutrition.
29% of gastroenterologists work side gigs (Becker’s GI & Endoscopy)
About 29 percent of U.S. gastroenterologists take on additional work to supplement their full-time incomes, according to Medscape’s “Gastroenterologist Compensation Report.”
Physician opinions vary on surveillance colonoscopies in older adults with prior adenomas, survey finds (MDedge)
Physician recommendations for surveillance colonoscopies vary based on several factors, including patient age, health, adenoma risk, and physician specialty, according to a national survey.
Marketing Building Blocks for Self-employed Physicians (Medscape)
Marketing an independent medical practice has evolved rapidly in the past decade, but self-employed physicians who haven’t changed so swiftly can still make up ground.
Functional Dyspepsia? Consider Prescribing a 3D Headset (GI & Endoscopy News)
Virtual reality, which has been shown to reduce both acute and chronic pain in a number of clinical settings, was found to improve symptoms in patients with functional dyspepsia in a new study.
Heads up: Novitas to hold CRC claims in certain jurisdictions (AGA)
Patients and providers in certain areas of the country can expect to be impacted by a claims processing issue.
AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease (AASLD)
Fibrosis progression in NAFLD is influenced by many factors, but lifestyle changes can help reduce NAFLD advancement.
ACG revamps guidelines for managing acute lower GI bleeding, ‘more data is needed’ (Healio)
The guidelines include new recommendations for risk stratification and reversal agents for patients on anticoagulants.
FDA clears IND application to treat excessive stool frequency in patients with J-pouches (Healio)
The FDA cleared the investigational new drug application for a live biotherapeutic biologic drug intended for patients with ileal pouch-anal anastomosis who experience excessive stool frequency.
VIDEO: Curricula is ‘just scratching the surface’ on incorporating DEI into GI training (Healio)
ASGE’s DEI subcommittee, Yakira David, MD, MBBS, outlined the importance of emphasizing DEI in gastroenterology training.

Network with GI tech thought leaders (AGA)

Oshi Health Again Named to New York Digital Health 100 List (PR Web)

The Covid emergency in the U.S. ends May 11. HHS officials say here’s what to expect (CNBC)

FDA has now cleared more than 500 healthcare AI algorithms (HealthExec)

CVS is buying Oak Street Health in $10.6B deal, and moves into primary care (Chief Healthcare Executive)

Why the growth of gut-tech could transform female health outcomes (Femtech World)

Recommendations Issued for Diabetes-Specific Colonoscopy Preparation (Endocrinology Advisor)

More physicians died from COVID-19 in pandemic’s early days than expected: study (Fierce Healthcare)

Fecal Microbiota Transplant Found Effective for Immune-Mediated Colitis (GI & Endoscopy News)

Do Advanced Endoscopy Fellows Get Enough Training in ESD? (GI & Endoscopy News)

Videos: Interviews with GI Leaders  (Scope Forward Show/NextServices)

COVID-19: The Way Forward for Gastroenterology Practices
COVID-19 is a double whammy of both clinical and business disruption. This ebook will help you explore possible scenarios and be a guide in your plans for the future.
04 Feb 2023

Curated GI articles February 3rd, 2023: FDA approves neurostimulator for incontinence | Study: Virtual GI care saves $10k per patient

Curated GI articles February 3rd, 2023:
FDA approves neurostimulator for incontinence | Study: Virtual GI care saves $10k per patient
Podcast: Robbie Allen, CEO of One GI (Becker’s GI & Endoscopy)
Robbie Allen (CEO of One GI) discusses the future of physician employment in the midst of dwindling numbers of independent physician groups, different generational perspectives on work, and more.
FDA approves 4th-generation neurostimulator for fecal incontinence, overactive bladder (Healio)
The FDA has approved Axonics Inc’s fourth-generation R20 rechargeable sacral neuromodulation system for bladder and bowel dysfunction.
Clinical Trial Results Demonstrate Oshi Health’s Multidisciplinary GI Care Improves Patient Outcomes with Savings Greater than $10,000 Per Patient Within 6 Months (PR Web)
The findings are important as digestive disorders are very common and have a high economic burden, affecting more than 70 million people in the U.S.
The future of GI (MDedge)
Judy A. Trieu, MD, MPH, the Editor-in-Chief and Advanced Endoscopy Fellow of the Division of Gastroenterology & Hepatology at the University of North Carolina at Chapel Hill, gives an overview of the articles regarding the future of GI.
Can AI Conquer the Late-Shift Dip in Colonoscopy Quality? (Medscape)
New research confirms that colonoscopies conducted later in an endoscopist’s shift are associated with a decline in adenoma detection and demonstrates that AI can help eliminate the problem.
Private Equity and Digital Health in 2023: Policy Updates and Trends to Watch (JD Supra)
The following serves as a broad overview of recent policy updates and areas of opportunity in 2023.
Salve Lucrum: The Existential Threat of Greed in US Health Care (JAMA Network)
The grip of financial self-interest in US health care is becoming a stranglehold, with dangerous and pervasive consequences.
Gut-Directed Hypnotherapy App Improves IBS Symptoms (GI & Endoscopy News)
A gut-directed hypnotherapy program conducted via a downloadable app was shown to improve GI symptoms —and to a degree that is similar to that seen in face-to-face therapy.
Ayble Health Recognized as the First and Only Gastroenterology Company to Achieve Certification from the Validation Institute for IBS and IBD Patient Outcomes (Ayble Health)
Ayble Health is tenacious in its pursuit to transform the standard of care for GI patients. Sam Jactel (CEO, Ayble Health) was recently interviewed on The Scope Forward Show.
Why are so many physicians quitting medicine? The real reasons revealed (KevinMD)
What will the health care system do with so many physicians leaving medicine? This article reviews two reasons physicians leave their current roles for something else.
Salvo Health & Gemelli Biotech partner to offer cutting-edge diagnostic testing for IBS and SIBO across 29 states (Salvo Health)
The partnership will provide access to advanced breath testing and IBS blood testing not generally available in most doctor’s offices.
Doctors, Get Ready for Your AI Assistants (WIRED)
Hospitals have begun using machine learning to help analyze and collect images, and the medical applications are endless.
10 gastroenterologists in the headlines (Becker’s GI & Endoscopy)
A compilation of gastroenterologists who have made news headlines, by Becker’s Healthcare.
Income Could Plunge for Out-of-Network Doctors (Medscape)
Out-of-network (OON) status has been financially advantageous for doctors, but in recent years, insurers have been making it harder to be OON.
Minimally invasive endoscopic therapies for gastro-oesophageal reflux disease (BMJ)
In recent years, several minimally invasive antireflux endoscopic therapies (ARET) have been developed which may play a role in bridging the unmet therapeutic gap.
New Treatment Recommendations for Early-Onset CRC (Medscape)
An international group of physicians has issued consensus recommendations for the diagnosis and management of patients with early-onset colorectal cancer (eoCRC).
Assessment of the Role of Artificial Intelligence in the Association Between Time of Day and Colonoscopy Quality (JAMA Network)
The findings suggest AI systems may be a potential tool for minimizing time-related degradation of colonoscopy quality.
‘Evidence supports’ de-escalating combination therapy in patients with IBD after 1 year (Healio)
Providers should consider de-escalating combination therapy with immunomodulators to monotherapy after 1 year in patients with inflammatory bowel disease, according to a presenter at the Crohn’s and Colitis Congress.

Register: 2023 AGA Tech Summit (AGA)

Young, gifted and Black: 3 GIs making an impact (AGA)

Virginia lawmakers push for greater coverage of colon cancer screening costs (Becker’s GI & Endoscopy)

It’s ‘telehealth vs. no care’: Doctors say Congress risks leaving patients vulnerable (News Medical)

‘I Cry but No One Cares’: Physician Burnout & Depression Report 2023 (Medscape)

4 gastroenterology, endoscopy facility openings in 2 weeks (Becker’s GI & Endoscopy)

Video: Medical Uses of ChatGPT (The Medical Futurist)

Patients with IBD, ‘higher social vulnerability’ inadequately screened for mental health (Healio)

Combination biologic therapy for ulcerative colitis (The Lancet GI & Hepatology)

Predicting Barrett’s Esophagus, Esophageal Adenocarcinoma 5 Years Before Diagnosis (GI & Endoscopy News)

Videos: Interviews with GI Leaders  (Scope Forward Show/NextServices)

COVID-19: The Way Forward for Gastroenterology Practices
COVID-19 is a double whammy of both clinical and business disruption. This ebook will help you explore possible scenarios and be a guide in your plans for the future.
30 Jan 2023

Curated GI articles January 27th, 2023: Connecticut GI Joins GI Alliance | ASC colonoscopy 2023 reimbursements

Curated GI articles January 27th, 2023:
Connecticut GI Joins GI Alliance | ASC colonoscopy 2023 reimbursements
GI Alliance Expands to East Coast with Connecticut GI Partnership (PR Newswire)
GI Alliance has announced a partnership with Connecticut GI, expanding GI Alliance’s presence into the Northeast and its 15th state.
Broadening Horizons: Why Gastroenterologists Should Consider a Career in Obesity Medicine
(Springer Nature)
In this paper, we will make the case for choosing a career in obesity medicine for GI fellows and practitioners.
Tips for getting involved with industry (MDedge)
This article offers a variety of ways that gastroenterologists can engage with the industry to achieve a mutually beneficial relationship.
EndoSound® Receives Investment From AGA’s GI Opportunity Fund (Business Wire)
EndoSound was granted Food and Drug Administration (FDA) Breakthrough Device designation in July 2021.
Is It Time for a More Personalized Approach to CRC Screening? (Medscape)
A new study confirms that the 10-year screening colonoscopy interval is safe and could even be extended in some adults at average risk for CRC.
How colonoscopy reimbursement is expected to change for ASCs in 2023 (Becker’s GI & Endoscopy)
Medicare ASC payments for colonoscopies with lesion removals and colonoscopies and biopsies are expected to increase in 2023, according to VMG Health’s “ASCs in 2022: A Year in Review” report.
Computer-Assisted Detection and Diagnosis Can Improve ADR, Reduce Costs (GI & Endoscopy News)
The incorporation of computer-assisted detection and diagnosis in colonoscopy can improve ADR. But can technology replace endoscopist training?
Should you sell your medical practice to a private equity group? (Medical Economics)
Healthcare practitioners are feeling the squeeze. Does staying small make sense for your practice anymore?
Sanofi, CytoReason expand AI deal into IBD (Pharmaphorum)
Tech company CytoReason has announced it has signed a multi-year, multimillion dollar deal with Sanofi to deliver AI for drug discovery and development in the field of IBD.
Smartwatches, wearable technology ‘may hold promise’ to identify, predict IBD flare (Healio)
Wrist-horn smart watches and wearable technology that monitors heart rate variability may help identify and predict flares of IBD.
Michigan Medicine gastroenterologist no longer works at university amid falsified data allegations (Becker’s GI & Endoscopy)
Chung Owyang, MD, a former gastroenterology researcher at Ann Arbor-based Michigan Medicine allegedly falsified data in multiple publications.
For This Physician, Retirement Is An Opportunity (Next Avenue)
A retired gastroenterologist tells of being a mentor to pre-med students, and what he and the students have gained from their discussions about the profession.
Is Food Sensitivity Testing a Scam? (NY Times)
Food sensitivity tests promise to supply answers. But do these tests work? Here’s what the experts have to say.
The Impact of Cascading Accountability on Specialty Practices: Time for a Nested Solution (CGH Journal)
Understand the perspective of the authors on the direction gastroenterology needs to take and why it cannot be a standalone solution, but rather needs to be integrated within other solutions.
Only Half of Folks With Stool Test Positive for Colon Cancer Get Follow-Up Colonoscopy (The Independent)
Many people undergo a stool test to screen for colon cancer but a new study finds too few follow up with a colonoscopy when that test warns of a possible cancer.
AI doctor will see you now: ChatGPT takes medical exams (Cyber News)
A group of researchers had the viral chatbot take the same US medical licensing exams as aspiring doctors. It performed “comfortably within the passing range,” they said.
Can Tech Giants Take Over Healthcare? (The Medical Futurist)
Could tech giants just take over healthcare? Here is a list of relevant factors you need to consider when thinking about what will happen in the next decade.
5 IBD updates from the 2023 Crohn’s & Colitis Congress® (AGA)
Less restrictive diets for Crohn’s disease, preoperative use of biologics, ultrasounds to monitor UC and more.

Register: 2023 AGA Tech Summit (AGA)

SF Interview- Jactel: “Being patient centered is different than being patient driven” (NextServices)

Young doctors are earning more. Will it be enough? (MDLinx)

Microbiome startup cuts 95% of remaining staff in 3rd layoff in 9 months (Boston Business Journal)

AGA risk assessment tool aids patient, physician decision-making for Crohn’s therapy (Healio)

Geneoscopy completes PMA filing for colorectal cancer home test (BioWorld)

FDA approves drug for treatment-resistant metastatic colorectal cancer (Becker’s GI & Endoscopy)

Virginia lawmakers push to cover cancer screenings costs, honors late local delegate (WSET)

Pediatric Gastroenterology: Physician Burnout (Physician’s Weekly)

Gastroenterology and Urology for Certified Medical Scribe Professionals (PR Newswire)

Videos: Interviews with GI Leaders  (Scope Forward Show/NextServices)in GI

COVID-19: The Way Forward for Gastroenterology Practices
COVID-19 is a double whammy of both clinical and business disruption. This ebook will help you explore possible scenarios and be a guide in your plans for the future.
21 Jan 2023

Curated GI articles January 20th, 2023: CellMax blood test for CRC | One GI expands in Virginia | Racial disparities in IBD

Curated GI articles January 20th, 2023:
CellMax blood test for CRC | One GI expands in Virginia | Racial disparities in IBD
Gastroenterology gains 1,128 physicians over 5 years (Becker’s GI & Endoscopy)
Gastroenterology gained 1,128 active physicians from 2016 to 2021, according to the Association of American Medical College’s “Physician Specialty Data Report.”
One GI® Expands Virginia Footprint Again (PR Newswire)
One GI®, the Home for Independent Gastroenterology, expands Virginia footprint again with Gastroenterology Associates, PC, partnership.
Healthcare Private Equity Down But Not Out, Report Finds (RevCycleIntelligence)
2022 was the second biggest year on record for healthcare private equity despite an uncertain and inflationary market hampering activity by the end of the year.
CellMax Life Announces Positive Results From Prospective Multisite Study of Novel Blood Test to Detect Colorectal Cancer and Pre-Cancer (PR Web)
Data shows 92% sensitivity for colorectal cancer and 55% sensitivity for precancerous advanced adenomas at 91% specificity.
Focus on six key areas for successful physician partnerships (Physicians Practice)
Entering a physicians partnership is not a process that should be rushed through nor taken lightly.
Unclogging the Pipes of Your GI Practice‍ (Telebelly)
Russ Arjal MD (Co-founder and CMO, Telebelly Health) provides insights to improve GI care for patients
America’s physicians are getting older, women are gaining ground, and more data on doctors (Chief Healthcare Executive)
The Association of the American Medical Colleges released a report that offers more insight on the nation’s physician workforce.
At-home bowel cancer tests could help reduce colonoscopies (EurekAlert)
Screening for bowel cancer using at-home faecal immunochemical tests could help to reduce the frequency of colonoscopies for some at above-average risk individuals.
Blood test could help predict which patients with colon cancer need chemotherapy after surgery: Study (ABC News)
A blood test under study may soon be able to help many patients with colon cancer decide whether they need chemotherapy after surgery, or if they can safely skip it.
Digital Health Funding Slows In 2022: Is The Hype Fading Or Is It A Temporary Setback ? (Workweek)
While 2022’s total digital health funding disappointed many, it was anything but unexpected.
Regenstrief Institute research scientists study online colorectal cancer risk calculators (EurekAlert)
Regenstrief Institute and Indiana University School of Medicine research scientists have conducted a study of online colorectal cancer risk calculators.
FIT DNA Screening Results Have Multiple Implications for Follow-up Colonoscopy (GI & Endoscopy News)
Colonoscopies performed after abnormal fecal immunochemical DNA tests are associated with greater detection of lesions, longer withdrawal times and recommendations for shorter intervals.
Top 100 hospitals for gastrointestinal care by state, per Healthgrades (Becker’s GI & Endoscopy)
A list of top hospitals for gastrointestinal care listed by Healthgrades in 2023 by state.
MedPAC asks Congress to increase physician payments (Healio)
The Medicare Payment Advisory Commission, or MedPAC, has recently voted to recommend that Congress increase 2024 Medicare payments for physicians and other health services.
Racial Disparities Seen in Use of IBD Medical Therapy (Pharmacy Practice News)
Black patients with inflammatory bowel disease are less likely to be treated with immunomodulator or biologic therapies than white IBD patients, according to a recent study in a large U.S. cohort.
Advanced colorectal neoplasia prevalence remains low 10 years after negative colonoscopy (Healio)
Screening colonoscopy has been shown to reduce colorectal cancer incidence and mortality by enabling detection and removal of precancerous lesions.
Scant Evidence for Proton Pump Inhibitor Role in Gastric Cancer (Medscape)
The available evidence suggests that proton pump inhibitors (PPIs) do not cause gastric cancer, researchers say.
Helping your patients with NAFLD lose weight (AGA)
Hear key takeaways from AGA’s Clinical Practice Update on NAFLD management.

More Hot headlines in GI

Register: 2023 AGA TeRegister: 2023 AGA Tech Summit (AGA)

SF Interview- Jactel: “Being patient centered is different than being patient driven” (NextServices)

Oshi Health Adds Distinguished Physician-Scientist and Upcoming AGA President Dr. Maria T. Abreu to Medical Advisory Board (PR Web)

Physician Sues AMA for Defamation Over 2022 Election Controversy (Medscape)

‘Clinical paradox’? Bariatric surgery may protect from GI cancers (MDedge)

Novel IgG-Based Elimination Diet Shown to Improve IBS Outcomes (GI & Endoscopy News)

EndoTheia Inc. Announces FDA Breakthrough Device Designation for Technology to Improve Endoscopic Surgery (BusinessWire)

Digesting 2022 and looking forward to 2023 in IBD therapeutics (Healio)

Videos: Interviews with GI Leaders  (Scope Forward Show/NextServices)ch Summit (AGA)

A 2022 Look Back: Increasing GI Expertise with 19 New Providers (MNGI Digestive Health)

Biomerica Appoints Mayo Clinic Gastroenterologist, Dr. Brian E. Lacy, to the Company’s Scientific Advisory Board (Globe Newswire)

Q&A: Gravity’s role in IBS pathogenesis, symptoms: A new hypothesis (Healio)

Dayton Gastroenterology, LLC., Now Incorporates First Artificial Intelligence System for Enhanced Colonoscopy Screenings (PR Newswire)

Longitudinal gut microbial signals are associated with weight loss: insights from a digital therapeutics program (MedRxiv)

Immune checkpoint inhibitor–related gastrointestinal adverse events (MDedge)

The effect of active video games on cognitive functioning in clinical and non-clinical populations: A meta-analysis of randomized controlled trials (Science Direct)

AGA Offers Key Guidance on Managing Subepithelial GI Lesions (Medscape)

At J.P. Morgan healthcare conference, Exact Sciences CEO describes pivotal meeting for Cologuard development (Lab Pulse)

Videos: Interviews with GI Leaders  (Scope Forward Show/NextServices)

COVID-19: The Way Forward for Gastroenterology Practices
COVID-19 is a double whammy of both clinical and business disruption. This ebook will help you explore possible scenarios and be a guide in your plans for the future.
15 Jan 2023

Curated GI articles January 13th, 2023: Geneoscopy CRC test shows 94% sensitivity | ModifyHealth raises $10M

Curated GI articles January 13th, 2023:
Geneoscopy CRC test shows 94% sensitivity | ModifyHealth raises $10M
Geneoscopy’s Noninvasive Colorectal Cancer Screening Test Demonstrates High Sensitivity and Specificity in Large Pivotal Clinical Trial (PR Newswire)
The CRC-PREVENT trial included 8,289 individuals with diverse racial, ethnic, and socioeconomic backgrounds across more than 2,900 zip codes in all lower 48 states.
SF Interview- Jactel: “Being patient centered is different than being patient driven” (NextServices)
In this episode, Praveen Suthrum speaks with Sam Jactel (CEO, Ayble Health) about his experience transitioning from being a GI patient to leading a digital health startup, the challenges facing the industry. Tune in to gain insights on his journey and more.
Private equity changes workforce stability in physician-owned medical practices (Medical Xpress)
The findings are the latest in a line of research to suggest private equity firms are increasing pressure to maximize profits.
ModifyHealth Secures $10 Million Series B Investment to Fuel Growing Demand for Its Medically Tailored Meals and Food as Medicine Platform (PR Newswire)
Diet-related chronic conditions continue to rise, accounting for nearly 75% of all health care dollars spent in the US.
Physician Growth Partners advises Gastroenterology Associates in transaction with One GI (EIN Newswire)
The transaction bolsters One GI’s existing Northern Virginia footprint and will accelerate their growth in the Mid-Atlantic market.
Unio Health Partners announces a partnership with inSite Digestive Health Care (PR Newswire)
Unio’s partnership with inSite represents a significant expansion of its gastroenterology business and more than doubles the size of the platform.
Colonoscopy Prep Retail Website Breach Festered for Years (Bank Info Security)
Captify Health, a colonoscopy prep-focused management services company, notified about 244,300 patients that their personal information may have been compromised during a data breach.
Vivante Health Adds Cognitive Behavioral Therapy Digital Therapeutic to GIThrive Digestive Health Platform (Vivante Health)
The new feature, called IThrive™, is the first CBT solution to be integrated into a comprehensive digestive health platform that has been proven to reduce healthcare spend and improve participants’ quality of life.
‘Spread the wealth,’ utilize team-based care to combat growing GI provider shortage (Healio)
The phenomenon of people retiring early because of burnout or leaving their institutions to work in a different field is detailed in the cover story.
Proximal ADR could become important new quality metric (MDedge)
Dr. Kosinski and colleagues analyzed retrospective claims data from all colonoscopies performed between 2016-2018.
Key Insights on Diagnostic Tools for NASH (GI Insights)
Dr. Charles Turck joins Dr. Kenneth Cusi to dive into diagnostic guidelines and share the latest updates on these tools.
The Coming Collapse of the U.S. Health Care System (TIME)
The massive financial drain imposed by staff shortages and use of locums has led to many health care facilities reaching the point of financial instability.
American College of Gastroenterology Guidelines Update: Diagnosis and Management of Celiac Disease (ACG)
This guideline presents an update to the 2013 ACG Guideline on the Diagnosis and Management of Celiac Disease with updated recommendations for the evaluation and management of patients with celiac disease.
What The FTC’s Proposed Ban on Noncompete Agreements Could Mean for Physicians, Other Clinicians (Medscape)
Many doctors would like to see noncompete agreements vanish, but some physicians still favor them.
John Carethers (President, AGA): Advice to build your career (AGA)
In this episode Dr. John Carethers, the current AGA President discusses career advice and about his important 80/20 rule in decision-making.
Digital health needs to prove its impact to providers, or go the way of the buffalo (Medical Economics)
As a barometer of the digital landscape, HLTH showed the digital health community must cut through the hype and start delivering better tools to physicians and patients.
Colonoscopies save lives. Why did a trial suggest they might not? (Nature)
A major clinical study raised questions about one of the most celebrated cancer-screening procedures available, but a close look at the data tells a different story.
Capital Digestive Care Announces Three Key Executive Leadership Changes (Globe Newswire)
The company’s board of directors has elected Dr. Roderick Kreisberg to be its president and chief operating officer and Dr. Dan Neumann to be its president and chief strategy officer.

More Hot headlines in GI

Register: 2023 AGA Tech Summit (AGA)

A 2022 Look Back: Increasing GI Expertise with 19 New Providers (MNGI Digestive Health)

Biomerica Appoints Mayo Clinic Gastroenterologist, Dr. Brian E. Lacy, to the Company’s Scientific Advisory Board (Globe Newswire)

Q&A: Gravity’s role in IBS pathogenesis, symptoms: A new hypothesis (Healio)

Dayton Gastroenterology, LLC., Now Incorporates First Artificial Intelligence System for Enhanced Colonoscopy Screenings (PR Newswire)

Longitudinal gut microbial signals are associated with weight loss: insights from a digital therapeutics program (MedRxiv)

Immune checkpoint inhibitor–related gastrointestinal adverse events (MDedge)

The effect of active video games on cognitive functioning in clinical and non-clinical populations: A meta-analysis of randomized controlled trials (Science Direct)

AGA Offers Key Guidance on Managing Subepithelial GI Lesions (Medscape)

At J.P. Morgan healthcare conference, Exact Sciences CEO describes pivotal meeting for Cologuard development (Lab Pulse)

Videos: Interviews with GI Leaders  (Scope Forward Show/NextServices)

COVID-19: The Way Forward for Gastroenterology Practices
COVID-19 is a double whammy of both clinical and business disruption. This ebook will help you explore possible scenarios and be a guide in your plans for the future.
13 Jan 2023

Sam Jactel, CEO of Ayble Health: “Being patient centered is different than being patient driven”

Sam Jactel, CEO of Ayble Health:
“Being patient centered is different than being patient driven”
At the end of the interview, Sam Jactel, GI patient turned CEO talks about Thomas Nagel the philosopher. In a paper from 1974, Nagel famously asked us to contemplate “What is it like to be a bat?” He suggested that you may be able to study the behavior of a bat but you can never really know what it’s like to be one.
Sam takes that analogy to his own GI condition. He was tired of looking for answers within the industry. He was tired of not being seen or heard. And he ended up figuring out a solution that worked for him. Then he thought why not help other patients like him. That prompted him to go from being the CEO of his own condition to becoming the founder and CEO of Ayble Health. This digital GI startup has raised $4.6 million from investors.
Watch this incredible interview. It’s a sign of the times. Expect more patients to become digital healthcare providers because the industry isn’t stepping up enough.
◘  From being a patient to becoming a CEO: The story behind starting up Ayble Health
◘  What is really missing in the GI industry?
◘  “The needs of the patients are either filtered or not heard”
◘  “The challenge that I have with GI and healthcare, in general, is that…”
◘  “Being patient-centered is different than being patient-driven”
◘  “With the tools that we have at our disposal, we are not driving optimal outcomes for patients like myself”
◘  “There aren’t even enough GIs to meet demand”
◘  Ayble Health raised $4.6 million. What triggered investor interest?
◘   The business model
◘  “We are part of the UCSF Rosenman Institute ADAPT program”
◘  The startup’s payment model
◘  Is the use of AI and machine learning really necessary?
◘  Is there a need for more and more digital GI companies?
◘  “We want patients to be seen”
◘  The future of GI & healthcare
◘  “I think that there’s too big of a gap currently between the claims that companies make in digital health and the evidence that supports it”

The Transcribed Interview:


Praveen Suthrum: Sam Jactel, founder, and CEO of Ayble Health. Welcome to The Scope Forward Show. I’m really looking forward to this conversation. This is one of the only times that I’m interviewing a patient who’s turned CEO, so really glad to have you. Welcome.
Sam Jactel:  It’s a pleasure to be here and really excited to be part of this long time listener, first time caller kind of thing. Really excited to have this conversation. And thank you to the audience also for their interest in what we’re building, how we’re building it, and really looking forward to the conversation.
Praveen Suthrum: Excellent. Sam, congratulations to you and your team for raising $4.6 million, and it’s a fantastic start. It is very reassuring for the industry and for digital GI that this space is growing, and it’s going to bloom in the coming years, and it’s very telling that you’re doing so in the IBS and IBD space. So, again, congratulations to you and your team.
Let me first start by asking you what the back story is here. How did you get started, and what is the story behind the name Ayble health?
Sam Jactel:  Happy to do that. Well, you know, I think at the end of the day, the story of Ayble is my own story. So I’ve been a GI patient for about ten years. I was diagnosed with ulcerative colitis, and  I’ve lived with that, and it’s not been the most linear journey, so to speak, and I think a lot of patients experience the same thing. But for me, I was diagnosed back in about 2014, and I was actually misdiagnosed a couple times before I got my final diagnosis. And over the past, you know, 8-9-10 years, I have seen five different gastroenterologists at some of the world’s best academic medical centers. I have played around with half a dozen different drugs, oral or not, over the counter supplements, all those kinds of things to find a cocktail that worked for me.
And despite having access to the best care that I was able to get my hands on and to be able to afford it, which is not the case for a lot of people in the United States, I think we make those assumptions. I still fell out of remission. I had four significant flares in the last eight years, and I couldn’t live like that anymore. And one of the things that I realized was that we were only, or I as a patient was only really getting treated as part of a person right of going to the clinic. The drugs were available, certainly, but not always effective alone, and the diagnostics were there and all those kinds of things. But the second I walked out of the clinic; I didn’t have any support for any of the evidence based interventions that my physicians were recommending to me. And those things were things like elimination diets or just dietary interventions generally, things like mental health support and cognitive behavioral therapy or being able to see a GI psychologist. And the best I ever got was a pamphlet and instructions to go figure that stuff out on my own. That just didn’t seem like it was good enough. And we were missing an opportunity in the space to use the new technology that exists out there, right, the machine learning, the predictive artificial intelligence, and just generalized technical tools to reduce the cognitive burden on the patient and improve the likelihood that I was going to get to remission.
And so that was kind of our core thesis. And the inception of the company was in very early 2020. I had my most recent pretty big flare and I was bedridden, and I just sat there and I said, I can’t do this anymore. And what I ended up doing was kind of working with group of researchers at Massachusetts General Hospital, Brigham and Women’s, Northwestern, and building out essentially a personalized nutrition program that worked for me and that I realized I could systematize and standardize and expand upon that could potentially also help others. And so we’ve been around since 2020 and for two and a half years we have been in the clinic running clinical research on that approach.
And so our precision nutrition program, which is kind of our flagship program, is built on 20 years of research in the space and the intersection between diet and IBS and IBD, as well as two and a half years. Of our own primary clinical research now published in Gastroenterology Inflammatory Bowel Diseases and most recently clinical and translational Gastro Neurology and are now taking that. And some of the funding is going to the commercialization of this novel machine learning guided precision nutrition program for folks like myself. But at the end of the day, to answer your question, I solved my own problem and realized that maybe it could help others. And that was, I think, the inception of where we came from.
Praveen Suthrum: Let me ask very fundamental question before we get into the company stuff and the business stuff and all that, when you experience GI as an industry, as a patient, you went in and out of clinics, met different gastroenterologists and so on, what’s missing in the industry? You touched upon it. But I want to touch on the pain a little bit. If you don’t mind, what really missing that caused you a great deal of discomfort and made you wonder that something is really off with our system.
Sam Jactel: How long do you have, my friend? Look, I think there’s a lot that’s going really well in the space. So I serve also on the congressionally directed medical research program as a patient reviewer for IBD. And I’m seeing a lot of amazing research that’s being done. There are new drugs, there are new approaches to team-based care for GI. And I think that folks in the space coming around and it’s a growing ecosystem that is evolving and doing better.
I think that the problem that I have is not maybe necessarily a GI problem. I think it’s just a healthcare issue. And I think the healthcare issue and something that I’m very passionate about is that healthcare is the only market where the end user doesn’t really have a voice. Here’s what I mean by that. So if you are a consumer of shoes, right, you will go and you’ll go to your store and you’ll purchase the pair of Nikes that you like and Nike will take that and say people are voting with their dollars. People like the gray shoes with the red stripe and I’m going to make more of those because that’s what people want and that’s what people need. And in health care there is no real direct way for someone like myself to vote with my dollars. And so what ends up happening is that the needs of the patient are either filtered or not heard.
And by that I mean the need of the patient is either filtered through the GI. The GI then gets to the pharma company, to the health system, to the insurer, and it’s like a game of telephone. It gets distorted. And I think the challenge that I have with GI and with healthcare in general, is that what then happens is that the companies that are building in the space, right, the ones that are innovative and putting tons and tons of dollars behind it. Are the health systems, are the insurers? Are the employers making those decisions with assumptions around where those patients are and what they actually need? And I think at the end of the day, we talk a lot about patient centricity. But unless you are patient, there’s always that little gap. I think that unless you live with it everyday, I don’t think you can make assumptions about what it’s like to live with it. And that’s where I think you see a lot of the statistics that are kind of shocking to people about what it’s like to suffer in that silence, right?
These conditions are taboo. Like we don’t like to talk about poop. I certainly didn’t. And so patients like myself just sit around there and we are unproductive at work. We are uncomfortable. There’s some really interesting statistics out there that just illustrate this and shock a lot of people like that. Patients like myself are willing to give up 15 years of our remaining life expectancy for an immediate cure today, that doesn’t exist. That’s like 20% of someone’s lifespan. That acute need and what it’s like to live with the condition, but also work in the environment of siloed places, of being essentially the CEO of your own condition because no one’s doing it for you. And I’ve had to do that.  Right? And you see, patients are incredibly resourceful. You have people building their own Excel models, people writing things in notebooks, gathering reams and reams of information so that they can problem solve for themselves in an environment that is not surrounding that patient. And that’s like a big piece to me, kind of in conclusion, is that being patient centered is different than being patient driven. And patients being founders, I think, is something that I’m really excited about, that we’re seeing in this space as well as other spaces.
Those are a couple of the observations that I’ve found and that I’ve lived with, and I figured, why not give it a shot? I’ve lived with it ten years of market research. There’s an opportunity to change the industry and the way that we think about it. By putting the patient as the driver, not as the passenger.
Praveen Suthrum: You know, Sam, my friends and colleagues in private practice are going to say, look, you know, you’re smart, you’re a biology major, you’ve done your MBA from Kellogg, and you have all these resources to put all this together and pay for diet, pay for drugs, and so on. But look, in our industry, we are driven based on what the insurance company pays. And so it’s managed care that is ruling. So who’s going to pay for all this food stuff? It sounds good. Who’s going to pay for it?
Sam Jactel: Yeah. And I think the core to this is, to me, there’s a trend into value based care.  Right? There’s a trend into at the end of the day, I think financial drivers are connected to outcomes drivers. I think the reality is, currently with the tools that we have at our disposal right now, we are not driving optimal outcomes for patients like myself. And the reason why is because we don’t have the tools. Right? And so one of the things that is really exciting about the way that we’re positioning ourselves is that we’re not disintermediating the physician at all. We want to keep you in the driver’s seat, and we want to be positioned as another tool in the physician’s toolbox to treat that patient. I’m also very empathetic, right? Like, you don’t have a lot of time talking to a patient. You also have not spent a huge amount of your medical career learning about nutrition, learning about mental health. You’re not an expert in that field. We also know that, like GI psychologists and GI specialized dietitians, there just aren’t enough to meet demand. There aren’t even enough GIs to meet demand. And so in that environment, we need to use technology to extend the care that a physician is able to provide to a patient.  Right? That’s the Hippocratic oath, right? That’s really important.
The other piece to it is if you can do that together as a holistic approach to care, you drive better outcomes and that drives cost down, but also make sure an ecosystem of GI as a treatment industry is long term sustainable. And I think that’s really important.  Right. We need to drive to those outcomes. And I think if we are only using a couple of tools and not all of them.
Praveen Suthrum: Excellent. Let’s talk a little bit more about the company. So what is the operational model and how do you plan to get paid? And why did investors choose to invest the money that they did in Ayble Health?
Sam Jactel: Yeah, it’s an exciting place to be. So very concretely. Ayble is a precision health platform for folks with gastrointestinal conditions, right? And I use the term precision health on purpose in the space. You’re probably familiar with precision medicine, right? You take a lot of variables from an individual that hopefully you can then use to predict what drug works best for that person. What about everything beyond the pill? And so we have built as a comprehensive ecosystem of care beyond the pill. And it’s built on the largest GI behavioral health database in the world. And in a way where we’re using machine learning and predictive AI to essentially gather a bunch of that data, continue to use it, so that eventually we’ll be in a situation where we can be able to predict for that individual what the right pathway through diet and through mental health will generate the most optimal outcomes. In addition to the pill.  Right. Not as a replacement. And so that’s kind of the ecosystem that we built.
Now, our go to market strategy is very similar to some of those companies that are category defining in other places, Headspace Health and a few others. And what it is, is essentially a B to C to B business model. One of the things that’s really exciting is that because we’ve been patients, we know where they are and we are going direct to consumer on purpose to be able to have that individual find evidence based resources in addition to the work that they’re currently doing in the clinic and then transitioning that into the enterprise. And so we sell through gastroenterologists and providers, primary care groups as well as that extra tool in that toolbox. And then of course through employers and insurers who are looking to drive down the claims volumes and drive down the per capita claims cost for patients like me who are incredibly expensive because we’re incredibly sick, that’s the kind of approach that we’re taking. But it’s very different. We’re not a virtual, like a telehealth platform right? We’ve kind of built out a digital therapeutic. We’ve wrapped around with hands on care, with a nutritionist and a health coach and a dietitian. And then we have last mile nutrition tools that allow us to suggest and find food products for someone to be that are compatible with their diet. What if you can’t eat onions? That’s hard enough, right? Alliums are poorly digested for most folks anyways, but it’s in everything. That’s why food tastes good, right? What if you’re also halal and you want to eat low sodium for other health reasons and you want to eat organic? Like, how do you do that? And so we built out this database of grocery store items, about 95% coverage across the United States. And we can filter for those foods that are compatible and not compatible for you, as well as pushing you recipes. And so really trying to wrap someone around with that full end to end support, not just leaving them with a recommendation and then still having them be at their own devices, but really combining end to end for them. To change the way they buy, change the way they cook, change the way they eat, and therefore feel good and adhere for the long term.
Praveen Suthrum: So do the patients reach out to you directly or do the GI doctors and primary care providers or anybody else, do they refer members to you? How does the business model work?
Sam Jactel: So for patients directly, it’s a subscription basis, right? Very similar to some of the other health and wellness companies that exist out there. For physicians, it’s a referral pathway. And so what we have built is there is an entire physician ecosystem of tools that we provide to that individual. So if you are the physician recommending Ayble to your patients, I think it’s very important for you to be in the driver’s seat and understand how that data comes back to you. And so we have a dashboard that allows you to monitor and say, okay, Sam’s doing well. And so the next time, right, the next 15 minutes I have with Sam, it’s more impactful, more powerful, and by the way, I’ve driven better outcomes. And we give you all that data. That’s really important and that’s a kind of referral pathway. And then for those enterprise clients, it’s very similar to some of those other groups, right? Per member per month payments or per member per year. And we also are very confident in our data because we published it to drive costs down. We go at risk with some of our fees as well. It’s really important, I think, to align those incentives.
Praveen Suthrum: Are you planning to work with insurance companies? There are some startups that are.
Sam Jactel: So we are part of the UCSF Rosenman Institute ADAPT  program. Recently we’re selected to be a finalist there. That’s a phenomenal ecosystem of insurance groups. I think the groups in that program, I think, manage about 100 million members in the United States. And so we’re working and having conversations with folks like those to be able to provide that is essentially a member benefit to their groups.
Praveen Suthrum: What is the pricing model?
Sam Jactel: The members pay a subscription and yes, yes, exactly. Like, it’s not much more expensive than Netflix, but it’s much more effective. And that’s how we’ve kind of orchestrated that. And then for the enterprise contracts, those are relatively standard enterprise contracts. It’s important to pay for that use. And so it’s those engaged members that we get paid for. And that I think is really important. And there are a couple of contracts that we’re putting together with some others that are like completely value based. We’re sharing on the dollar of savings and on the improvement of outcomes for those individuals.
Praveen Suthrum: So there’s a tendency in the digital health start-up community to apply AI and machine learning on everything. And one of the questions that I have, and I’d like to push back here a little bit, is that really necessary? Because what is the AI going to do? And is it not just a simple algorithm that you need versus a predictive mechanism? Because I think having been a patient, it’s probably more to do with not doing the wrong things versus doing certain specific things, maybe a combination of both. But as I understand IBS, IBD, it’s an act of removal and knowing the triggers and managing what those triggers are. And once it is set, it is set because I’m sure you’re not changing the recommendations or what you do too much after a point of time. Why is AI or machine learning required for something like this? What’s your response or reflection on this whole variability aspect?
Sam Jactel:  Look, I love that question because I think those terms are thrown around a lot and they’re either ill-defined or they’re used, but with no real purpose. And so I’m going to answer this question in two ways. One is I want to illustrate what it looks like to do this on your own, and I hope in illustrating that you’ll understand where these kinds of data models are really important, particularly around the diet piece. I think the other piece to this is our broader ambitions and what we’re trying to do with our company in defining a new gold standard of care on an Iterative basis.
So let me illustrate what it looks like first on the diet side, right? So let’s say a FODMAP pamphlet that gets given to a patient. The onus is then on that individual, you shouldn’t eat FODMAP for the rest of your life.  Right? It’s highly restrictive and that brings on additional problems and certainly very hard to adhere to. And there are some good encyclopaedia type resources to figure out what’s low or high or medium FODMAP, whatever that is. And the interesting thing is that there also is no real consensus about is it FODMAP? Is it nice guidelines? Is it other? The Mediterranean diet, the specific carbohydrate diet.
It’s a very kind of diffuse let me use FODMAP as an example. So you go through the process of eating very low FODMAP for quite a long time. And what that requires you to do is eliminate hundreds of foods, staples of your diet for quite some time, six, eight weeks, something like that. And then what you’re supposed to be doing is the reintroduction of that, because not all of those foods are individualized to you to be exacerbating symptoms or causing symptoms. And so you have to go through an iterative process of reintroducing one food every three to five days. And if you’re doing the math in your head, you have 100 foods reintroducing every three to five days, you’re talking about a year and a half of experimentation. And that’s not to say that then you also have to write down how you feel all the time and then connect the dots. And even working with a dietician, it’s incredibly complicated.
And so the machine learning and the AI tools are there to help reduce the cognitive load on that individual, to make it easier to gather that information and to draw conclusions from it. And the most important part of that is then you can use that to inform a better, faster, more effective program for the next patient on the basis of all the aggregated data and the identified data that we’ve gathered for others. And so it’s a positive flywheel that’s important that we’ve kind of innovated here and patented for this group. And so we take what’s, a year and a half long experimentation process, which, by the way, a lot of people start and never finish, and so you never get the outcomes out of it. And we collapse it to 12 to 16 weeks and proven that we’ve been Ayble to generate outcomes, right? So we improve outcomes for 81% of IBS and IBD patients, and for almost 70% of them, by the end of the program, we’ve gotten them to clinical remission as defined by the Symptom Severity Scores, right? The IBS symptom severity scores the CDI, et cetera. That’s really important.
I think the second part of my answer is that what we’re trying to do here is not just take the standard of care that exists in the clinic. We’ve talked about how it’s not effective, it doesn’t drive optimal outcomes for everybody. And so what we’re trying to do here is, on the basis of this incredible data ecosystem that we’ve developed, and we use that as a positive flywheel to continuously iterate that gold standard of care, right? It’s not just about making care virtual, but not changing outcomes. It’s about using the digital tools to make the outcomes better and more equitable and easier to access for everybody. I think that’s really exciting. And so that’s why it’s kind of like a very core problem that we solve with the ML and AI stuff, right? Same problem also with mental health that we’re working on. But the other piece is just what is our bigger ambition? You cannot get to precision health unless you gather that data, and that data cannot be interpreted unless you use tools like ML and AI. And so that’s kind of how we’re thinking about it. And of course, we may be incorrect, and the value of those models is that we can continue to get better and better over time. And that’s just we have to be humble in the way that we approach it. But that’s the vision.
Praveen Suthrum: One more question on the company and competition and all that. I would argue that there are other companies also in the wellness space that are taking similar approaches for digestive diseases. And there’s one at least that’s been through the FDA gate, taking a digital therapeutics approach. So does the world need yet another digestive disease digital GI company? Or this is the sign of the times. And I’m asking again, with all respect to the clinical side and the patient side of the story, I’m just asking a business question here.
Sam Jactel: It’s a really important question, and I’ll give you a like, but not the answer you want and then the answer that you want afterwards. I think the reality is a gigantic market and the needs are not solved yet. And so we need as many people in the space trying different things as possible to be able to change the lives of patients like myself. And the diabetes market is a good example of this, right? There are half as many diabetes patients in the US. As there are GI patients. And there are hundreds of diabetes companies doing really interesting work, approaching it from different angles, and they’re all finding a good niche in the market and generating solid returns for investors and having sustainable business models. And I think we’re going to see that in GI. It’s a huge market. I think the other piece of this is just how you present yourself to the business ecosystem and what your go to market is. And I think the prescription digital therapeutics route is really exciting, right. And they’re doing a couple of other things, I think insomnia as well, and some other folks like Mahana Therapeutics, metaMe with the Regulora, they’re going through that model. It’s a different approach to the market where certainly there’s a value creation and value capture piece to this, right? They create a lot of value. They capture almost all the value that they generate because of the ecosystem that’s built, right. It’s just like a drug. But I don’t think that you’re going to be able to get the volume right. And I think the reality is that there are tons of people, right? If 25% of a commercially insured population has a GI diagnosis, and then another, let’s say 10 to15% have undiagnosed or under diagnosed conditions. You’re never going to be able to meet the demand with that model exclusively. And so that’s really important for us is like, we want to make this amazing new science and the innovations that we’ve developed accessible for as many people. And the reality is also that the conditions that we are trying to address are really hard to manage with one tool alone. And so I think there’s actually much more collaboration that can be in the system than we maybe expect, right? Because in my view, these are and conditions rather than or conditions. And by that I mean you should do your diet and you should do your psychology and you should do your drugs and you should do your physical.
There’s a lot, but it needs to be tailored to you as an individual, and someone needs to quarterback that. And in lieu of an ecosystem that makes that possible, we think the patient does it right, and we empower the physician to help extend that care as well. So that’s kind of the way that we’re thinking about it.
Praveen Suthrum: Very well answered. Thank you for sharing that perspective. If there’s a patient out there watching this or listening to this and thinking, hey, I want to be in his shoes, I want to turn CEO too, and take my problem head on, what advice would you have for them?
Sam Jactel: First, I think the most important thing, the reason why we’re called Ayble is that we want patients to feel seen in this world, because a lot of times we aren’t. And I told you about voting with dollars and stuff like that. I think it’s also uncomfortable to talk about. And so we are called Ayble because our goal is to make you be Ayble to go to restaurants without fear, be Ayble to travel, be Ayble to be defined by something other than your condition. And so to those patients that are looking at it, we see you, we’ve been in your shoes, and it’s a tough place to be, but we’re trying to solve for what you are living with all the time. And to those that are taking that next step of being not just a CEO of their own condition, but trying to be the CEO of their own company, let’s say, a gift and a curse. I think the gift is that you have a unique understanding of the problem that you’re solving for your ultimate users. And I think that’s really, really exciting because you know what to build, you know what not to build.
I think the curse is me search rather than research. And by that I mean, like, I am an end of one. And we need to be very humble in our understanding that my experience as a white male, privileged, educated individual is not the case for everybody else. And if you make the false assumption that you are your only customer or that all your customers look and talk and feel and live like you, you’re going to have a bad time.  Right. It’s not going to be appropriate. And so the thing that is really exciting about that opportunity is also its potential downfall. And so for those individuals that are looking to go into this space and take advantage of their however many years of research by being that patient, I think it’s also important to hear others and to include others as part of that. And we’ve talked to thousands and thousands of patients, and we use that to inform our decisions. It’s not just me.  Right. And that’s really important, I think we don’t talk a lot about, but yeah, I think that’s a key insight that I learned.
Praveen Suthrum: Final two questions. What’s the future of GI and health care? From the lens that you’re seeing right now?
Sam Jactel: I won’t beat a dead horse. I think the future of healthcare is patient driven. Not just we talk in, like, loose terms about, oh, we are patient centric.  Right. It needs to be at the core of what the actual problem we’re solving, because we can’t get the outcomes unless the person at the end of the day who is sick gets better. And so I think that’s, like, really important.  Right. So the patient driven things, I think, will end up, whoever solves my needs as a patient, better, I think, will ultimately win in the market for a variety of reasons.  Right. Not just for outcomes, but also for contraction. I think the other piece to it is that we are very excited about this. You know, we’re running randomized controlled trials. We did three years of clinical research before we took a dollar from anyone. The bar for clinical evidence needs to keep going up, and it cannot be a non-inferiority thing. We need to keep pushing that up.  Right. That standard of care needs to continue to evolve. And we’re excited to be part of that new trend of first, we should be publishing more of our research, right. In clinical journals. We should be showing how we do that to people, and we should be empowering others to keep evolving. I welcome all the folks in the space to keep building that out and publishing that research. But I think that there’s too big of a gap currently between the claims that companies make in digital health, not just GI, but generally right. And the evidence that supports it. And I also don’t think that it’s good enough to refer to other research. I think the onus needs to be on digital health companies to run their own research of their own brand of doing that care and their innovations. I think it’s important to validate their novel innovations and what they’re contributing to the space. That’s a challenge, for sure.  It’s expensive. It’s hard to do well. But science is so important in this space, and I think we need to lead with evidence because that drives trust and it also drives outcomes and it drives sustainability from a business standpoint for everybody. So that’s, I think, my challenge to the space, it’s a challenge that we’ve issued ourselves. We’re not perfect at it, but it’s something that we’re really excited about.
Praveen Suthrum: So, Sam, in closing, I want you to reiterate that philosophical analogy that you shared with me before we started recording about being the bat versus knowing the bat. So I’ll let you share it, and then we’ll close.
Sam Jactel: I’m glad you can nerd out about this, but yes, I’ve been a big philosophy guy for a while, and there’s a phenomenal philosopher. His name is Thomas Nagel. And Thomas Nagel has an amazing article that I’m happy to share with this community as well, where he makes this proposition where he says, imagine you are the foremost scientist in the bat field, right? You know everything about the physiology of the bat. You know all the neurons, how they’re connected, the chemical signaling. You know how the whole system of the bat works. You know how the echolocation works. You know the difference between the signals and how they find their way through their environment while being functionally blind. You can know everything about the bat. But his proposition is that even though you know everything there is to know about a bat, you will never know what it’s like to be a bat and what it’s like to being this, I think, super important in this space. And the analogy is, I think, very connected to what it’s like to be a patient.  Right? And if we can think more like that, I think we’re really going to change the world.
Praveen Suthrum:  On that note, Sam Jactel. I’m so glad that you came on The Scope Forward Show. Wish you and your team all the best, and I really wish for more patients like you to step up, take action, and start companies in the GI space because there is a lot of need. Thank you once again.
Sam Jactel: Yeah, thank you so much for the opportunity. And I welcome the discussion with the rest of the GI community. Would love to chat with GIS, with other folks, kind of innovating in the space. And it’s a really exciting time. This is the right time and the right place to be building for people in this ecosystem. So go forth and prosper. I appreciate the opportunity. Thank you.


COVID-19: The Way Forward for Gastroenterology Practices
COVID-19 is a double whammy of both clinical and business disruption. This ebook will help you explore possible scenarios and be a guide in your plans for the future.